TG Therapeutics TGTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's EPS (diluted)?
- TG Therapeutics (TGTX) reported EPS (diluted) of $0.12 in Q1 2026.
- How has TG Therapeutics's EPS (diluted) changed year-over-year?
- TG Therapeutics's EPS (diluted) increased by 300.0% year-over-year, from $0.03 to $0.12.
- What is the long-term trend for TG Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), TG Therapeutics's EPS (diluted) has grown at a 1.9% compound annual growth rate (CAGR), from -$2.63 to $2.78.
- What does EPS (diluted) mean?
- The profit per share if all potential shares were issued.
- How do you interpret EPS (diluted)?
- A smaller gap between basic and diluted EPS indicates lower potential dilution risk for existing shareholders.
- How does EPS (diluted) compare across companies?
- Standardized metric used to assess the impact of equity-based compensation and convertible debt.